Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis

Clinical and Translational Oncology

Volumn 18, Issue 5, 2016, Pages 497-506

  Yu, X ^a,b   Zhang, Z ^a,b   Wang, Z ^a   Wu, P ^a   Qiu, F ^a,b   Huang, J ^a,b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Breast cancer; Clinicopathological features; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

CD8 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 17; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PREDICTIVE VALUE; SYSTEMATIC REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER STAGING; FEMALE; IMMUNOLOGY; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 84944699394     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1391-y     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.
2. Fan L, Strasser-Weippl K, Li J-J, St Louis J, Finkelstein DM, Yu K-D, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–89. doi:10.1016/s1470-2045(13)70567-9.
3. Mouawad R, Spano JP, Khayat D. Lymphocyte infiltration in breast cancer: a key prognostic factor that should not be ignored. J Clin Oncol. 2011;29(15):1935–6. doi:10.1200/jco.2011.35.4845.
4. Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
5. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010.
6. Raggi C, Mousa HS, Correnti M, Sica A, Invernizzi P. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2015. doi:10.1038/onc.2015.132.
7. Hu W, Li X, Zhang C, Yang Y, Jiang J, Wu C. Tumor-associated macrophages in cancers. Clin Transl Oncol. 2015. doi:10.1007/s12094-015-1373-0.
8. Tang X. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013;332(1):3–10. doi:10.1016/j.canlet.2013.01.024.
9. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011;121(10):3804–9. doi:10.1172/jci57099.
10. Perdiguero EG, Geissmann F. Identifying the infiltrators. Science. 2014;344(6186):801–2. doi:10.1126/science.1255117.
11. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–22. doi:10.1038/ni.2703.
12. Cruz-Merino L, Barco-Sanchez A, Henao Carrasco F, Nogales Fernandez E, Vallejo Benitez A, Brugal Molina J, et al. New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol. 2013;2013:785317. doi:10.1155/2013/785317.
13. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13. doi:10.1200/JCO.2009.23.7370.
14. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011;71(17):5678–87. doi:10.1158/0008-5472.can-11-0431.
15. + lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705–13. doi:10.1038/bjc.2013.634.
16. Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2013;1(4):625–32. doi:10.3892/mco.2013.107.
17. Liberati AAD, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100.
18. Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology. 2013;63(2):225–33. doi:10.1111/his.12156.
19. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, et al. Tumor-infiltrating gamma delta T lymphocytes predict clinical outcome in human breast cancer. J Immunol. 2012;189(10):5029–36. doi:10.4049/jimmunol.1201892.
20. Ma Y, Adjemian S, Mattarollo Stephen R, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38(4):729–41. doi:10.1016/j.immuni.2013.03.003.
21. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73. doi:10.1038/nri2216.
22. Yuting Ma SRM, Adjemian Sandy, Yang Heng, Aymeric Laetitia, Dalil Hannani J, Catani Paulo Portela, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. 2014;74(2):436–45. doi:10.1158/0008-5472.CAN-13-1265.
23. Alizadeh D, Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res. 2014;74(10):2663–8. doi:10.1158/0008-5472.can-14-0301.
24. Ye J, Ma C, Wang F, Hsueh EC, Toth K, Huang Y, et al. Specific recruitment of regulatory T cells in human breast cancer. Cancer Res. 2013;73(20):6137–48. doi:10.1158/0008-5472.can-13-0348.
25. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother. 2012;62(2):383–91. doi:10.1007/s00262-012-1343-0.
26. Oncology OJotASoC. Abstracts American Society of Clinical Oncology 50th Annual Meeting. J Clin Oncol. 2014;32(15S):48s.
27. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL et al. Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;7.
28. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2):e58–68. doi:10.1016/s1470-2045(13)70477-7.
29. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–12. doi:10.1016/j.coi.2011.12.009.
30. + T regulatory cell-mediated suppression. Immunity. 2009;30(5):636–45. doi:10.1016/j.immuni.2009.04.010.
31. Pagès FKA, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–51.
32. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611–8. doi:10.1093/annonc/mdt556.
33. Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(3):793–805. doi:10.1007/s10549-011-1554-7.
34. Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667–76. doi:10.1007/s10549-013-2581-3.
35. Sun S, Fei X, Mao Y, Wang X, Garfield DH, Huang O, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother CII. 2014;63(4):395–406. doi:10.1007/s00262-014-1519-x.
36. + infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011;127(1):99–108. doi:10.1007/s10549-010-0987-8.
37. + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949–55. doi:10.1200/JCO.2010.30.5037.
38. + lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res BCR. 2012;14(2):R48. doi:10.1186/bcr3148.
39. + tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. Indian J Cancer. 2013;50(3):239–44. doi:10.4103/0019-509X.118744.
40. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;. doi:10.1200/JCO.2013.55.0491.
41. Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012;43(10):1688–94. doi:10.1016/j.humpath.2011.12.013.
42. Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013;16(1):32–9. doi:10.4048/jbc.2013.16.1.32.
43. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res BCR. 2011;13(6):R126. doi:10.1186/bcr3072.
44. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7. doi:10.1200/JCO.2011.41.0902.
45. Matkowski RGI, Halon A, Lacko A, Szewczyk K, Staszek U, Pudelko M, et al. The prognostic role of tumor-infiltrating CD4 and CD8 T lymphocytes in breast cancer. Anticancer Res. 2009;29(7):2445–51.